Drug Trial Radar · NCT07698535
Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
64
Planned (sponsor's estimate)
Start
Nov 15, 2026
Primary completion
Jul 5, 2029
Study completion Jul 5, 2029
Sponsor
- Lead sponsor
- University of WashingtonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Institute for Prostate Cancer Research (IPCR)
- First posted
- Jul 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial studies whether measuring circulating tumor deoxyribonucleic acid (ctDNA) tumor fraction (TF) can be used to help guide the early stopping (discontinuation) of lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617) in patients with castration-resistant prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Many types of tumors tend to lose cells or release different types of cellular products including their deoxyribonucleic acid, which is referred to as ctDNA, into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for the disease to grow, spread, or get worse or come back after a period of improvement. ctDNA TF is a type of ctDNA measurement. Research has shown ctDNA TF may be a promising way to predict which patients will respond to 177Lu-PSMA-617 treatment. Measuring ctDNA TF may help doctors identify which patients may benefit from changing treatments sooner, which may be an effective way to guide early 177Lu-PSMA-617 treatment discontinuation in patients with metastatic castration-resistant prostate cancer.
Conditions
- Metastatic Castration-Resistant Prostate Adenocarcinoma
- Stage IVB Prostate Cancer AJCC v8
Interventions
Lutetium Lu 177 Vipivotide TetraxetanDrug
Given IV
Cell-free Circulating Tumor DNA AssayProcedure
Undergo ctDNA TF testing
Computed TomographyProcedure
Undergo CT
DocetaxelDrug
Given IV
PSMA PET ScanProcedure
Undergo PSMA PET
Single Photon Tomography and Computed Tomography ScanProcedure
Undergo SPECT/CT
Biospecimen CollectionProcedure
Undergo blood sample collection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and proportion among those recruited with detectable circulating tumor deoxyribonucleic acid (ctDNA) tumor fraction who undergo randomizationTime frame: Up to 2 cycles (Cycle length = 6 weeks)
- Number of patients screened, enrolled, evaluable for C2D1 ctDNA tumor fraction and for who cycle 3 is administeredTime frame: Up to cycle 3 administration (Cycle length = 6 weeks)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.